Articles

Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription

Department of Internal Medicine III, Ulm University, Ulm, Germany;Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
Genomics Core Facility, Ulm University, Ulm, Germany
Department of Internal Medicine III, Ulm University, Ulm, Germany
Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
Department of Internal Medicine III, Ulm University, Ulm, Germany
Department of Internal Medicine III, Ulm University, Ulm, Germany
Department of Internal Medicine III, Ulm University, Ulm, Germany
Department of Internal Medicine III, Ulm University, Ulm, Germany
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA;New York Genome Center, New York, NY, USA
Department of Internal Medicine III, Ulm University, Ulm, Germany
Department of Internal Medicine III, Ulm University, Ulm, Germany
Wissenschaftlicher Service Pharma GmbH (WiSP), Langenfeld, Germany
Service d’Hématologie Biologique, Hôpital Avicenne, Bobigny, France
Service d’Hématologie, Hôpital Pitié-Salpêtrière, Paris, France
Service d’Hématologie Clinique, CHU de Reims, Reims, France
Department of Internal Medicine I, University of Cologne, Cologne, Germany
Department of Internal Medicine I, University of Cologne, Cologne, Germany
Department of Internal Medicine I, University of Cologne, Cologne, Germany
Department of Internal Medicine I, University of Cologne, Cologne, Germany
Department of Internal Medicine III, Ulm University, Ulm, Germany;Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
Department of Internal Medicine III, Ulm University, Ulm, Germany
Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
Department of Internal Medicine I, University of Cologne, Cologne, Germany
Department of Internal Medicine III, Ulm University, Ulm, Germany
Department of Internal Medicine III, Ulm University, Ulm, Germany
Vol. 105 No. 5 (2020): May, 2020 https://doi.org/10.3324/haematol.2019.217307